SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001144204-19-022091
Filing Date
2019-04-30
Accepted
2019-04-30 06:34:27
Documents
5
Effectiveness Date
2019-04-30

Document Format Files

Seq Description Document Type Size
1 DEFA14A tv519838_defa14a.htm DEFA14A 24081
2 GRAPHIC image_001.gif GRAPHIC 20471
3 GRAPHIC image_002.gif GRAPHIC 34396
4 GRAPHIC image_003.gif GRAPHIC 9750
5 GRAPHIC image_004.gif GRAPHIC 2694
  Complete submission text file 0001144204-19-022091.txt   117800
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38128 | Film No.: 19778306
SIC: 2834 Pharmaceutical Preparations